Testosterone Therapy in Breast Cancer Survivors (Glaser, Glaser-Garbrick, Dimitrakakis; Androgen Society Poster, 2021) reports findings from a prospective IRB-approved observational study examining the use of subcutaneous testosterone or testosterone plus aromatase inhibitor (T/T+AI) implants in women with a history of breast cancer. The study followed patients across disease stages to evaluate local recurrence, systemic recurrence, and breast cancer–specific survival over multiple years of therapy, contributing to the ongoing clinical discussion around hormone therapy use in this population.

This work is frequently referenced because it evaluates real-world outcomes in breast cancer survivors receiving testosterone-based implant therapy, with a focus on recurrence patterns and disease-specific survival over time.